Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Holly J Pederson

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Menopause (New York, N.Y.)|September 2, 2025
Considerations for hormone therapy use in survivors of breast cancerHolly J Pederson
Menopause (New York, N.Y.)|December 26, 2025
Breast cancer screening in midlife and beyondHolly J Pederson
Menopause (New York, N.Y.)|July 2, 2019
Clinical care of women with intermediate breast cancer riskHolly J Pederson
Menopause (New York, N.Y.)|January 10, 2023
Use of exogenous hormones in those at increased risk for breast cancer: contraceptive and menopausal hormones in gene carriers and other high-risk patientsHolly J Pederson, Pelin Batur
Seminars in Oncology|June 10, 2020
Updates in hereditary breast cancer genetic testing and practical high risk breast management in gene carriersHolly J Pederson, Ryan Noss
Maturitas|October 17, 2025
Polygenic risk scores for breast cancer: Progress, challenges, and clinical integrationJerry S Lanchbury, Holly J Pederson
Obstetrics and Gynecology|April 8, 2021
Controversies in Hereditary Cancer ManagementMariam M AlHilli, Holly J Pederson
BJC Reports|November 8, 2024
An apparent quandary: adoption of polygenics and gene panels for personalised breast cancer risk stratificationJerry S Lanchbury, Holly J Pederson
BJC Reports|November 8, 2024
Commentary: Why is genetic testing underutilized worldwide? The case for hereditary breast cancerHolly J Pederson, Steven A Narod
Cleveland Clinic Journal of Medicine|July 3, 2023
Surgical de-escalation: Are we ready for 'observation' of benign high-risk breast lesions found on core needle biopsy?Holly J Pederson, Debra Pratt, Benjamin C Calhoun
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Menopause (New York, N.Y.)|September 2, 2025
Considerations for hormone therapy use in survivors of breast cancerHolly J Pederson
Menopause (New York, N.Y.)|December 26, 2025
Breast cancer screening in midlife and beyondHolly J Pederson
Menopause (New York, N.Y.)|July 2, 2019
Clinical care of women with intermediate breast cancer riskHolly J Pederson
Menopause (New York, N.Y.)|January 10, 2023
Use of exogenous hormones in those at increased risk for breast cancer: contraceptive and menopausal hormones in gene carriers and other high-risk patientsHolly J Pederson, Pelin Batur
Seminars in Oncology|June 10, 2020
Updates in hereditary breast cancer genetic testing and practical high risk breast management in gene carriersHolly J Pederson, Ryan Noss
Maturitas|October 17, 2025
Polygenic risk scores for breast cancer: Progress, challenges, and clinical integrationJerry S Lanchbury, Holly J Pederson
Obstetrics and Gynecology|April 8, 2021
Controversies in Hereditary Cancer ManagementMariam M AlHilli, Holly J Pederson
BJC Reports|November 8, 2024
An apparent quandary: adoption of polygenics and gene panels for personalised breast cancer risk stratificationJerry S Lanchbury, Holly J Pederson
BJC Reports|November 8, 2024
Commentary: Why is genetic testing underutilized worldwide? The case for hereditary breast cancerHolly J Pederson, Steven A Narod
Cleveland Clinic Journal of Medicine|July 3, 2023
Surgical de-escalation: Are we ready for 'observation' of benign high-risk breast lesions found on core needle biopsy?Holly J Pederson, Debra Pratt, Benjamin C Calhoun
Pageof 4